These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33543660)

  • 1. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
    Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A
    J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
    Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B
    Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.
    de Los Reyes E; Lehwald L; Augustine EF; Berry-Kravis E; Butler K; Cormier N; Demarest S; Lu S; Madden J; Olaya J; See S; Vierhile A; Wheless JW; Yang A; Cohen-Pfeffer J; Chu D; Leal-Pardinas F; Wang RY
    Pediatr Neurol; 2020 Sep; 110():64-70. PubMed ID: 32684372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
    Lewis G; Morrill AM; Conway-Allen SL; Kim B
    J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of Intraventricular Cerliponase Alfa for CLN2 Disease.
    Schulz A; Ajayi T; Specchio N; de Los Reyes E; Gissen P; Ballon D; Dyke JP; Cahan H; Slasor P; Jacoby D; Kohlschütter A;
    N Engl J Med; 2018 May; 378(20):1898-1907. PubMed ID: 29688815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease.
    Hammon K; de Hart G; Vuillemenot BR; Kennedy D; Musson D; O'Neill CA; Katz ML; Henshaw JW
    Clin Transl Sci; 2021 Sep; 14(5):1810-1821. PubMed ID: 34076336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.
    Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerliponase Alfa: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(11):1247-1249. PubMed ID: 28589525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.
    Cherukuri A; Cahan H; de Hart G; Van Tuyl A; Slasor P; Bray L; Henshaw J; Ajayi T; Jacoby D; O'Neill CA; Schweighardt B
    Clin Immunol; 2018 Dec; 197():68-76. PubMed ID: 30205177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
    Schaefers J; van der Giessen LJ; Klees C; Jacobs EH; Sieverdink S; Dremmen MHG; Spoor JKH; van der Ploeg AT; van den Hout JMP; Huidekoper HH
    Orphanet J Rare Dis; 2021 May; 16(1):221. PubMed ID: 33990214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
    Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW
    Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
    Wibbeler E; Wang R; Reyes EL; Specchio N; Gissen P; Guelbert N; Nickel M; Schwering C; Lehwald L; Trivisano M; Lee L; Amato G; Cohen-Pfeffer J; Shediac R; Leal-Pardinas F; Schulz A
    J Child Neurol; 2021 May; 36(6):468-474. PubMed ID: 33356800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution.
    Vuillemenot BR; Kennedy D; Reed RP; Boyd RB; Butt MT; Musson DG; Keve S; Cahayag R; Tsuruda LS; O'Neill CA
    Toxicol Appl Pharmacol; 2014 May; 277(1):49-57. PubMed ID: 24642058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survival analysis of ventricular access devices for delivery of cerliponase alfa.
    Craven CL; Gissen P; Bower R; Lee L; Aquilina K; Thompson DNP
    J Neurosurg Pediatr; 2022 Jan; 29(1):115-121. PubMed ID: 34624852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 Disease and ICV-Enzyme Replacement Therapy: A Case Report.
    Schwering C; Apostolidou S; Deindl P; Christner M; Knobloch JK; Herrmann J; Kobbe R; Schulz A; Singer D; Ebenebe CU
    Neuropediatrics; 2022 Oct; 53(5):381-384. PubMed ID: 35843218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment.
    Mortensen A; Raebel EM; Wiseman S
    Orphanet J Rare Dis; 2022 Jan; 17(1):19. PubMed ID: 35045884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Pearce JW; Vansteenkiste DP; Bibi K; Lim S; Robinson Kick G; Castaner LJ; Sinclair J; Chandra S; Nguyen A; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Aug; 197():108130. PubMed ID: 32622066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report.
    Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C
    Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.